The global biosurgery market is anticipated to grow at a CAGR of 6.8% during the forecast period (2021-2027). The key companies across the globe are focusing on the adoption of different growth strategies including capacity expansion, mergers and acquisitions, geographical expansion, new product launch, and product innovation to remain competitive in the marketplace. For instance, in September 2020, Takeda Pharmaceuticals co. ltd. has done an agreement with Corza Health Inc., to divest its TachoSil Fibrin Sealant Patch. This fibrin sealant patch is a surgical patch to deliver safe, fast, and reliable bleeding control. Takeda Pharmaceutical Company received around $421 million in cash for divesting its TachoSil to Corza Health.
Browse the full report description of "Global Biosurgery Market Size, Share & Trends Analysis Report by Products (Adhesion Barriers, Soft Tissue Management(mesh/patch), Bone Graft Substitutes, Surgical Sealants, Hemostatic Agents, and Staple Line Reinforcement Static Agents), By Applications (Neurological Surgeries, General Surgeries, Cardiovascular Surgeries, Orthopedic Surgeries, Gynecology Surgeries, Urological Surgery, Thoracic Surgeries, and Others (Ophthalmic Surgeries) Forecast, 2021-2027" at https://www.omrglobal.com/industry-reports/biosurgery-market
Moreover, in September 2020, CryoLife, Inc., a cardiac and vascular surgery company focused on aortic disease, has announced that it has acquired Ascyrus Medical LLC, a Florida-based company. Ascyrus’s first aortic arch remodeling device named Ascyrus Medical Dissection Stent used for the treatment of Type A aortic dissections. Apart from it, in October 2018, Atrium Medical Corporation, a subsidiary of Getinge, has done an agreement to divest its biosurgery business to HJ Capital 1, the parent company of SeCQure Surgical Corporation, a medical device company.
In December 2019, Johnsons & Johnsons, a medical devices company, has announced that Ethicon has launched VISTASEAL Fibrin Sealant (Human) to assist surgeons to manage bleeding during surgery. It is a combination of fibrinogen and thrombin, clotting proteins found in human plasma. When applied to the bleeding portion, it forms adherent, and durable clots and assist to sustain hemostasis (stoppage of bleeding), even in high-risk patients. However, the key player's strategies such as the expansion of its product distribution by making new agreements, launches of new products, and mergers and acquisitions in the market are to drive the global biosurgery market during the forecast period.
Market Coverage
o By Product
o By Application
o North America
o Europe
o Asia-Pacific
o Rest of the World
Key questions addressed by the report
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
Global Biosurgery Market Report Segment
By Products
o Biological
o Synthetic
o Cell-based matrices
o Bone morphogenetic proteins
o Demineralized bone matrix
o Synthetic graft extender
o Fibrin Sealants
o Collagen Based Adhesives
o Synthetic agents
o Tissue –Adhesive Glues
By Application
Global Biosurgery Market Report Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/biosurgery-market